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The ischemic penumbra refers to tissue at risk of infarction where perfusion is inadequate to
support neuronal function, but just adequate to maintain cell viability (1). This dysfunctional, but
salvageable tissue has been the target of all acute stroke therapies (2), and this concept underpinned
the successful trials of intravenous thrombolysis using t-PA (3). Advanced imaging, including
diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI) MR and CT perfusion
(CTp), was developed to rapidly identify stroke patients with still present penumbra, who were
thought to be the best candidates for reperfusion therapies. However, early studies, using different
methods for identifying penumbra, differentmeasures of outcome, and different time-windows have
not consistently confirmed the benefit of selecting treatment candidates on the basis of imaged
penumbra. Therefore, some outstanding questions surround the optimal modality for imaging the
penumbra, themost reliable thresholds in eachmodality, how long the penumbra can bemaintained
under what subject-specific circumstances, and the functional significance of persistent penumbra.
These questions have taken on particular importance in light of the results of five recently completed
randomized clinical trials showing benefit of endovascular treatment of stroke, when patients are
carefully selected and treated on a timely basis. These trials include MR CLEAN (4), ESCAPE (5);
EXTEND-IA (6), and two trials that have not been published, but the results of which have been
presented at the International Stroke Conference [SWIFT PRIME (7) and REVASCAT1]. These
trials have used different criteria to select patients for treatment, including different modalities of
imaging (CT vs. MRI), but those that have shown the highest odds of favorable functional outcome
have selected patients on the basis of having both a small core infarct, and either large volume of
penumbral tissue (“tissue at risk”) (6, 7) or the presence of moderate–good collateral circulation (5)
that would support penumbral tissue in the face of proximal occlusion.
These recent studies, together with an earlier successful pilot trial of another thrombolytic agent
that used MR-based selection of target penumbral patients (8) have shown the importance of
selecting patients on the basis of the presence of penumbral tissue, but underscore the urgency of
defining appropriate thresholds with imaging that can be obtained swiftly in order to maximize the
efficiency of intervention.While the gold standard for both irreversibly ischemic core and penumbra
has been defined by PET (2), PET cannot be obtained rapid enough to provide a practical guide for
acute stroke treatment. Some centers are able to obtain rapid MRI, while most will rely likely on
multiphase CT angiogram and/or CTp to guide intervention. It is critical that the stroke field adopts
valid and reliable thresholds using any of these modalities to select candidates for intervention.
Toward this goal, two MR vs. PET back-to-back studies have proposed validated MR-perfusion
thresholds, based on small samples (9, 10). This Research Topic consists of a set of papers that
addresses some of the controversies and intriguing questions that remain.
Kaesemann and colleagues (11) evaluated the impact of severe extracranial ICA stenosis
on MRI measures of penumbra in patients with middle cerebral artery occlusion who were
1Davalos A, Jovin T. REVASCAT – clinicalTrials.gov, NCT01692379
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imaged within 4.5 h of onset. They evaluated core infarct volumes,
mean transit time (MTT), Tmax, cerebral blood volume (CBV),
and cerebral blood flow (CBF) maps, as well as tissue at risk (Tmax
>6 – infarct volume). The presence of the additional extracranial
stenosis did not affectmeasured infarct volume,MTT,Tmax, or tis-
sue at risk, but had a small influence on CBV. They hypothesized
that extracranial stenosis may lead to ischemic preconditioning
that results in improved collateral circulation and a consequent
increase in CBV in the presence of acute stroke.
Wouters and co-workers (12) discuss proposed imaging crite-
ria, including diffusion-FLAIR mismatch, for selecting patients
who wake up with stroke and or have unknown onset. They
point out that there are currently no data for selecting one set of
criteria over another, but argue that identifying patients who have
penumbral tissue with imaging should allow intravenous and/or
endovascular treatment of many of these patients.
Leigh and colleagues (13) hypothesized that the conflict-
ing conclusions from two large endovascular trials, MR RES-
CUE and DEFUSE 2, regarding the usefulness of MRI diffu-
sion and perfusion imaging for selecting candidates for treat-
ment were due to differences in definitions of core infarct and
“tissue at risk.” MRI scans from patients evaluated for endovas-
cular therapy were processed using the methods published in
the two trials. The volume of core infarct was consistently
smaller when defined by MR RESCUE criteria than DEFUSE
2 criteria. The volume of tissue at risk was consistently larger
when defined by the MR RESCUE criteria than DEFUSE 2 cri-
teria. When these volumes were used to classify MRI scans,
9 out of 12 patients (75%) were classified as having salvage-
able tissue by MR RESCUE, while only 4 out of 12 patients
(33%) were classified as having salvageable tissue by DEFUSE
2 criteria.
Marsh and co-workers (14) present two patients who under-
went endovascular treatment with very different outcomes. They
argue that robust collateral circulation supported a prolonged
penumbra in the patient who showed minimal progression to
infarct and outstanding functional outcome despite a delay in
treatment.
Agarwal and colleagues (15) compared quantitative hemody-
namic measures of CTp (volumes of penumbra defined by CBF,
or PenCBF, and penumbra defined by MTT, or PenMTT), a
visually defined CBF/CBV ASPECTS ratio, and a visually rated
collateral circulation on CTA. They found that both PenCBF
and PenMTT showed trends to decrease with increased time
since onset. The CBF/CBV ASPECTS ratio, which was related
to the PenCBF, significantly decreased with increased time since
onset. In contrast, the rating of collateral response was not related
to time since onset. These results raise some questions as to
whether the presence of collaterals can be used as a surrogate
for the presence of penumbral tissue in selecting candidates for
intervention.
Campbell and colleagues (16) discuss challenges of imaging
the penumbra and provide useful guidelines. They also discuss
scenarios in which recanalization and reperfusion are discordant:
both cases in which there is recanalization without reperfusion
and reperfusion without recanalization (via enhanced retrograde
collateral flow). Finally, they discuss infarct growth and the fact
that there is sometimes persistent hypoperfusion that accounts for
clinical deficits.
Motta et al. (17) investigated the clinical consequences of per-
sistent hypoperfusion. They found that uninfarcted but hypop-
erfused tissue, with a threshold of 4–5.9 s delay on time-to-peak
(TTP) maps on PWI occasionally persists for days and is associ-
ated with cognitive deficits such as aphasia or neglect. Further-
more, change in volume of hypoperfused tissue of 4–5.9 s delay
and change in volume of ischemic tissue on DWI over the first
few days were independently associated with change in cognitive
function. Sebastian et al. (18) also show that persistent cortical
hypoperfusion caused by arterial stenosis can cause aphasia or
neglect (in cases of purely thalamic infarct), although some cases
of aphasia after thalamic stroke are likely due to cortical dysfunc-
tion (diaschisis) in the absence of hypoperfusion caused by arterial
stenosis.
Finally, Scalzo and colleagues (19) argue that there are likely
to be detailed features of CT and MRI that are not currently
tapped, which may provide useful information for guiding stroke
intervention. Use of computer vision and machine learning to
incorporate aspects of imaging data that we may not realize are
relevant may yield data-driven approaches to clinical decision-
support.
This Research Topic thus addresses important and timely con-
cerns surrounding the issue of how the ischemic penumbra can
best be rapidly identified on imaging in order to contribute to
management of acute stroke.
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